P. J. Molenaar

Measuring Rivaroxaban in a clinical laboratory setting, using common coagulation assays, Xa inhibition and thrombin generation

A. Leyte, J. Dinkelaar, P. J. Molenaar, 2012, Clinical chemistry and laboratory medicine.

Procoagulant myeloblast‐derived microparticles in AML patients: changes in numbers and thrombin generation potential during chemotherapy

H. ten Cate, M. van Schilfgaarde, M. C. Trappenburg, 2011, Journal of thrombosis and haemostasis : JTH.

Pre-acquisition system assessment of the Sysmex® Coagulation System CS-2100i and comparison with end-user verification; a model for the regional introduction of new analysers and methods

A. Leyte, P. J. Molenaar, 2011, Clinical chemistry and laboratory medicine.

In vitro assessment, using thrombin generation, of the applicability of prothrombin complex concentrate as an antidote for Rivaroxaban

M. Ninivaggi, A. Leyte, H. Brinkman, 2013, Journal of thrombosis and haemostasis : JTH.

Hemostasis during low molecular weight heparin anticoagulation for continuous venovenous hemofiltration: a randomized cross-over trial comparing two hemofiltration rates

J. Wester, H. O. Oudemans-van Straaten, M. van Schilfgaarde, 2009, Critical care.

Procoagulant myeloblast‐derived microparticles in AML patients: changes in numbers and thrombin generation potential during chemotherapy

M. C. Trappenburg, A. Leyte, W. Terpstra, 2011, Journal of thrombosis and haemostasis : JTH.